Ipilimumab/nivolumab/pembrolizumabVitiligo like depigmentation: 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1765卷 / 1期

关键词：

D O I：

10.1007/s40278-019-65961-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：204 / 204

相关论文

共 50 条

[1] Ipilimumab/nivolumab/pembrolizumabVitiligo and hypophysitis: 7 case reports
Reactions Weekly, 2020, 1795 (1) : 166 - 166
[2] Ipilimumab/pembrolizumabVitiligo: 4 case reports
Reactions Weekly, 2018, 1711 (1) : 160 - 160
[3] Ipilimumab/nivolumab/vemurafenibUveitis: 3 case reports
Reactions Weekly, 2016, 1606 (1) : 93 - 93
[4] Ipilimumab/Nivolumab/PembrolizumabHypophysitis: 3 case reports
Reactions Weekly, 2024, 2037 (1) : 222 - 222
[5] Ipilimumab/nivolumab/pembrolizumabGastroparesis: 3 case reports
Reactions Weekly, 2021, 1871 (1) : 216 - 216
[6] Ipilimumab/nivolumab/pembrolizumabMyocarditis: 3 case reports
Reactions Weekly, 2022, 1909 (1) : 303 - 303
[7] Ipilimumab/nivolumab/pembrolizumabThyroiditis: 3 case reports
Reactions Weekly, 2019, 1748 (1) : 268 - 268
[8] Ipilimumab/nivolumab/pembrolizumabSarcoidosis: 3 case reports
Reactions Weekly, 2017, 1678 (1) : 109 - 109
[9] Ipilimumab/nivolumab/pembrolizumabVarious toxicities: 3 case reports
Reactions Weekly, 2021, 1861 (1) : 175 - 175
[10] Ipilimumab/nivolumab/pembrolizumabVarious toxicities: 3 case reports
Reactions Weekly, 2021, 1840 (1) : 228 - 228

← 1 2 3 4 5 →